(Exempt) Validation of the Genomic Prostate Score (GPS) as a Predictive Biomarker of Oncologic Outcomes in Men with High-Risk Prostate Cancer (NCCN Guidelines v1.2025)
Study Description
Eligibility
7.1.1 Men diagnosed with primary adenocarcinoma of the prostate
7.1.1.1 Control group: NCCN High Risk (v4.2024 criteria)
7.1.1.2 Test group: NCCN High Risk (v1.2025 criteria), with clinical stage ≥ T3b or primary Gleason pattern 5.
7.1.2 Prostate biopsy tissue available for analysis
7.1.3 Minimum length of tumor: 0.2 mm
7.1.4 Minimum follow up time of 5 years post-diagnosis
7.2
7.2.1 Prostate biopsy with pure intraductal carcinoma without evidence of invasive prostatic adenocarcinoma
7.2.2 Prostate biopsies with pure prostatic ductal carcinoma, or ductal carcinoma in association with acinar adenocarcinoma
7.2.3 Insufficient amount of prostate biopsy tissue available to perform the analysis without exhausting samples.
7.2.4 Previous malignancy (apart from skin cancer)
7.2.5 Renal transplant or renal dialysis
7.2.6 Cardiovascular, respiratory or other comorbidities that preclude invasive intervention
7.2.7 No record of consent